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Abstract
Cathepsin D is a lysosomal aspartic protease found in all mammalian cells and is considered to be one of the main
catabolic proteinases. Cathepsin D has been suggested to play a role in the metastatic potential of several types of cancer. A
high activated cathepsin D level in breast tumor tissue has been associated with an increased incidence of relapse and
metastasis. High levels of active cathepsin D have also been found in colon cancer, prostate cancer, uterine cancer, and ovarian
cancer. Hydroxyethyl isosteres with cyclic tertiary amine have proven to be clinically useful as inhibitors of aspartyl proteases
similar to cathepsin D in activity, such as the HIV-1 aspartyl protease. We have undertaken the design, via computer molecular
modeling, and the synthesis of (hydroxyethyl) amine isostere inhibitors, which are similar to potent inhibitors of the aspartyl
HIV-1protease. We now report the preparation of six compounds that contain novel hydroxyethyl isosteres with cyclic tertiary
amines.

Introduction

Aspartyl proteases are among the most biologically
important proteolytic enzymes. Some of the more serious
medical problems, such as cardiac disease, AIDS,
Alzheimer's disease, as well as colorectal and breast cancer,
and other cancers, either result directly from, or are
characterized by, uncontrolled aspartyl protease activity
(Mimoto et al., 2000; Moore et al., 2000; Nakaya et al.,
2001; Messmer et al., 2001). The HIV-1 aspartyl proteinase,
which is responsible for the maturation of HIV into the
infectious viral particles (Darke and Heff, 1994), has become
an important therapeutic target for treatment of acquired
immunodeficiency syndrome (AIDS) (Debnath, 1999;
Alterman et al., 1998; Backbro et al., 1997; Hulten et al.,
1997).
Cathepsin D is an aspartyl lysosomal protease similar to
the HIV-1 aspartyl protease in substrate specificity.
Cathepsin D is clearly involved in the process of tumor
invasion and metastasis (Thorpe et al., 1998; Vetvicka et al.,
1997; Laury-Kleintop et al., 1995; Losch et al., 1996;
Mordente et al., 1998; Reig et al., 1996). In fact, cathepsin D
has recently emerged as a prognostic indicator in several
cancers, including breast cancer (Thorpe et al., 1998),
prostrate (Mordente et al., 1998), and colon (Reig et al.,
1996). Also cathepsin D has recently been associated with
the development of Alzheimer's disease (Moore, 2000).
Specific proteinase inhibitors, useful in investigations of the
mechanisms
and pathways of intracellular protein

degradation, could lead to the development of therapeutic
agents for treatment of many types of carcinomas, as well as
Alzheimer's disease.
Pepsin, renin, cathepsin D, and recently the HIV-1
aspartyl protease are among the best characterized aspartyl
proteases. Allof these proteases are inhibited by pepstatin A
(Kratzel et al., 1998; Kratzel et al., 1999; Scholtz et al., 1994),
a pentapeptide like compound which contains two unusual
-amino acid statines
[(3S,4S)-4-amino-3-hydroxy-6methylheptanoic acid]. Pepstatin, which contains a reactive
hydroxyl group, forms the tetrahedral intermediate by
reacting with the essential carboxyl group in the active site
of the proteinase (Rich and Bernatowicz, 1985; Payne et al.,
1991). Although pepstatin A was found to be a potent
inhibitor of the HIV-1aspartyl protease, the peptidic nature
of the inhibitor resulted in poor bioavailability. In order to
improve bioavailability and improve in vivo half-life, recent
work has focused on smaller inhibitors that contain a nonpeptide functionality in place of the peptide bond cleavage
site of the substrate (Skulnick et al., 1997; Reich et al., 1996).
The use of hydroxyethyl isosteres with cyclic tertiary amines
has lead to compounds with enhanced oral absorption
(Smith et al., 1997). In recent years the (R)hydroxyethylamine insert was incorporated as a key
component of many clinically used, highly potent, HIV-1
protease inhibitors. Initially several compounds that contain
hydroxyethyl amine isosteres with flexible alkyl amines
were developed (Beaulieu et al., 1997), but they suffered
limited in vivo half-lives and were not therapeutically useful.
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ig. 1. Target molecules with peptide and non-peptide portions

Molecular modeling (HYPERCHEM) has shown that a
six member ring forming the tertiary amine may be able to
orient the backbone of the inhibitor toward a bioactive
conformation while providing more of a non-peptide
functionality which greatly improves the half-life of the
inhibitor in vivo. A comparison of the structural and
stereochemical requirements of the S3', 82' and Sj' as well
as the Sj, S2, and the S3' subsites of cathepsin Dalong with
projected interactions with various inhibitor side chains
suggests modifications which may be introduced to improve
potency. Several investigators have shown, through
crystallographic studies or molecular modeling, that either a
cyclohexyl group of a reduced phenylalanine or the phenyl
group of a phenyalanine-type statine (hydroxyethylene) or
hydroxyethyl amine is easily positioned in the Sj site of the
HIV-1 aspartyl protease (Payne et al, 1991; McConnell et
al., 1991). Other studies show that a bulky amine or amide
might fit reasonably well into the S2 and S3'' sites (Paul et
al., 1995). Therefore, we set out to synthesize compounds
that contain a peptide portion to accommodate the Sj, S2,
and S3 subsites and a non-peptide hydroxyethyl isostere
portion with a cyclic tertiary amine to accommodate the Sj',
S2', and S3', enzyme subsites. The general structure of our
synthetic target is shown in Figure 1.

''

Materials and Methods
Anhydrous solvents were "anhydrous grade" from
Aldrich Chemical Company. Dry solvents were distilled
from sodium just prior to use. Allother solvents were HPLC
grade. Reagents were purchased from Sigma- Aldrich
Chemical Company. Thin layer chromatography (TLC) was
run on Whatman PE SIL G/UV 250 urn silica gel plates.
Column chromatography was run on either Aldrich TLC
grade silica gel 2-25um particle size BET surface area -500
m2/g, average pore diameter 60A, or Sigma Sephadex LH20, lipophilic, bead size 20-100 urn. The *H NMR spectra
were collected either on a Bruker 200 MHz AC 200
superconducting spectrometer or on a Hitachi 60 MHz

R1200 RS NMR spectrometer. lH NMR of final
compounds and major intermediates were collected on the
200 MHz spectrometer, while the spectra of minor
intermediates were collected on the 60 MHz NMR
spectrometer. The spectral data were processed NTNMR
software produced by TeleMag.
available
BOC-L-phenylalaninal
(10.2
mmol)
36.5
in
BOC-L-phenylalanine methyl ester
g,
to
(THF)
was
chilled
-80°C
200 mL dry tetrahydrofuran
under a N2 atmosphere. The cold solution was slowly
treated with 92 mL (91.25 mmol, 2.5 equivalents) of 1 M
diisobutyl aluminum hydride (DIBAL) in hexanes over 20
minutes. The mixture was stirred at -80°C under N2 for four
hours. The reaction was quenched by the addition of 100
mL 0.01 M aqueous HC1. The mixture was then partitioned
between the layers of dichloromethane (400 mL) and 5%
aqueous sodium potassium tartarate (400 mL). The aqueous
layer was extracted
with another 400 mL of
dichloromethane. The organic layers were combined and
washed three times with 250 mL portions of distilled water.
The organic layer was dried over anhydrous magnesium
sulfate and concentrated under reduced pressure to produce
a colorless viscous oil. The crude aldehyde was purified by
silica gel flash chromatography using dichloromethane as
the mobile phase, (final mass 5.80 g). TLC (CH2C12) Rf =
0.39. *H NMR (CDCI3/TMS, 60MHz) 5 1.0 (9H, s), 2.3
(2H, d), 4.1 (1H, m), 4.9 (1H, m), 6.9 (5H,s), 9.9 (lH,s).
3(S)-BOCamino-4-phenyl-1-butene (2).~A precooled (0
°C) solution of triphenylmethyl phosphonium bromide
(12.8 g, 0.035 mol) in 50 mL dry THF was slowly treated
over 10 minutes with 20 mL of 1.6 Mn-butyl lithium (0.032
mol) under N2 atmosphere. The solution was stirred for four
hours at 0°C. A solution of BOC-L-phenylalaninal (5.0 g,
0.020 mol) in 25 mL dry THF was added. The mixture was
allowed to warm to room temperature and was refluxed for
24 hours under N2 atmosphere. The reaction was cooled
and then quenched by the addition of 100 mL 0.01 M
aqueous HC1 saturated with NaCl. The mixture was
extracted three times with 200 mL portions of ether. The
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organic layers were pooled, dried over anhydrous MgSO 4,
and concentrated under reduced pressure to give a white
powder (3.5 g). TLC (ether/hexanes, 1/1, v/v) Rf = 0.36. !
H
NMR (CDCI3/TMS, 60MHz) 8 1.0 (9H, s), 2.2 (2H, d), 4.2
(1H, m), 4.9 (1H, m), 5.1 (2H, d, J=10 Hz), 5.3 (1H, m), 6.9
(5H,s).
3(S)-BOCamino-4-phenyl-2-oxirane (3).~A solution of
5.5 g (4 equivalents, 32 mmol) meta-chloroperoxybenzoic
acid (MCPBA) in 200 mL methylene chloride was mixed
with a solution of 2.0 g (8 mmol) 3(S)-BOCamino-4-phenyl1-butene (2) in 100 mL methylene chloride. The mixture
was stirred at room temperature for 24 hours. The mixture
was then filtered and concentrated under reduced pressure.
The oily residue was partitioned between the layers of ether
(400 mL) and distilled water (400 mL). The organic layer
was removed and saved. The aqueous layer was extracted
with another 400 mL ether. The ether layers were
combined, washed with distilled water (400 mL), 5%
aqueous NaHCO 3 (400 mL), and distilled water again (400
mL). The organic layer was dried over anhydrous
magnesium sulfate and concentrated under reduced
pressure to produce a mixture of epoxide diastereomers
(1.53 g). The diastereomers were separated by silica gel
(grade 710, 4-20 um, surface area 480 m2/g) column
chromatography (column size 4" dia. x 5' length) using 10%
ethyl acetate/hexanes as the mobile phase.
3(S)-BOCamino-4-phenyl-2(R)-oxirane (3a).~0.597 g.
0.21. lH NMR
TLC (35% ethyl acetate/hexanes) Rf
(CDCl3/TMS,200MHz) 5 0.9572 (9H, s), 2.451 (2H, d),
3.525 (2H, d), 3.705 (1H, d oft), 4.531 (1H, m), 4.715 (1H,
m, exchangable), 7.105 (5H,s).
(3b).~0.535 g.
3(S)-BOCamino-4-phenyl-2(S)-oxirane
=
(35%
acetate/hexanes)
ethyl
TLC
Rf
0.18. lH NMR
(CDCl3 /TMS,200MHz) 5 0.9805 (9H, s), 2.401 (2H, d),
3.529 (2H, d), 4.203 (1H, d oft), 4.502 (1H, m), 4.675 (1H,
m, exchangable), 7.059 (5H,s).

-

3(S)-BOCamino-4-phenyl-1-N-piperdine-2(S)-butanol
(4a). -Asolution of3a (1.0 g, 3.1 mmol) in 100 mL dry THF
was treated with 1.0 mL (10 mmol) piperdine. The solution
was refluxed for 48 hrs. The mixture was then cooled to
room temperature, concentrated under reduced pressure to
about one half its volume, and partitioned between ethyl
acetate (200 mL) and 5% aqueous sodium potassium
tartarate (200 mL) containing 1.0 g NaCl. The organic layer
was washed with distilled water (100 mL) and dried over
anhydrous magnesium sulfate. The solvent was evaporated
under reduced pressure to give a white solid (0.867 g). The
crude product was purified by silica gel column
chromatography (2.5 cm x 60 cm length) using 50% ethyl
acetate/hexanes as the mobile phase to give 0.673 g. TLC
(50% ethyl acetate/hexanes)
Rf = 0.54. lH NMR
(CDCl3/TMS,200MHz) 8 0.9892 (9H, s), 1.654 (2H, t),
1.768 (4H, m), 2.130 (4H, t), 2.443 (2H, d), 2.905 (2H, d ),

3.855 (1H, d of t), 4.4921 (1H, d of t), 4.925 (1H, m,
exchangable), 7.085 (5H,s).
3(S)-BOCamino-4-phenyl-1-N-pyrrolidine-2(S)-butanol
(4b).-A solution of 3a (1.0 g, 3.1 mmol) in 100 mL dry THF
was treated with 1.7 mL (20 mmol) pyrrolidine. The solution
was refluxed for 48 hrs. The mixture was then cooled to
room temperature, concentrated under reduced pressure to
about one half its volume, and partitioned between ethyl

acetate (200 mL) and 5% aqueous

sodium potassium
(200 mL) containing 1.0 g NaCl. The organic layer
was washed with distilled water (100 mL) and dried over
anhydrous magnesium sulfate. The solvent was evaporated
under reduced pressure to give a white solid (0.927 g). The
crude product was purified by silica gel column
chromatography (2.5 cm x 60 cm length) using 50% ethyl
acetate/hexanes as the mobile phase to give 0.673 g. TLC
(50% ethyl acetate/hexanes)
R f = 0.34. !H NMR
(CDCl3/TMS,200MHz) 5 0.9990 (9H, s), 1.859 (4H, t),
2.330 (4H, t), 2.456 (2H, d), 2.927 (2H, d ), 3.892 (1H, d of
t), 4.501 (1H, d of t), 4.935 (1H, m, exchangable), 7.125
(5H,s).
tartarate

3(S)-amino-4-phenyl-1-N-piperdine-2(S)-butanol
dihydrochloride (5a).~0.50 g of 4a was dissolved in 50 mL
cold (0°C) 2 MHC1 in chloroform. The mixture was stirred
at 0°C for 1hour. Cold diethyl ether (250 mL) was added to
induce precipitation of the product. The liquid was
decanted, and the precipitant was washed twice with cold
ether (100 mL). The crude solid was dissolved in 20 mL
methanol and then recrystallized by the addition of 250 mL
cold ether. The white solid was again washed twice with
cold ether (100 mL) and dried under reduced pressure (0.46
g). TLC (10% ethanol/ethyl acetate) Rf 0.35 lH NMR (
D2O, 60MHz) 5 1.7 (2H, t), 1.9 (4H, m), 2.2 (4H, t), 2.5 (2H,
d), 2.9 (2H, d ), 3.7 (1H, m), 4.5 (1H, m), 7.1 (5H,s).

-

3(S)-amino-4-phenyl-1-N-pyrrolidine-2(S)-butanol
dihydrochloride (5b).~0.55 g of 4b was dissolved in 50 mL
cold (0°C) 2 MHC1 in chloroform. The mixture was stirred
at 0°C for 1 hour. Cold diethyl ether (250 mL) was added to
induce precipitation of the product. The liquid was
decanted, and the precipitant was washed twice with cold
ether (100 mL). The crude solid was dissolved in 20 mL
methanol and then recrystallized by the addition of 250 mL
cold ether. The white solid was again washed twice with
cold ether (100 mL) and dried under reduced pressure (0.47
g). TLC (10% ethanol/ethyl acetate) Rf = 0.23 *H NMR
(D2O, 60MHz) 8 2.0 (4H, t), 2.3 (4H, m), 2.6 (2H, d), 3.0
(2H, d), 3.8 (1H, m), 4.4 (1H, m), 7.0 (5H,s).
General Procedure for Preparation of Carbobenzoxyamino acids (6a-c).--A solution of the appropriate amino
acid (0.050 moles ) in 250 mL 1 M aqueous NaOH was
chilled to 0°C and slowly treated (over 1 hour) with (0.055
moles) benzyl chloroformate. The mixture was stirred for
three hours at 0°C, allowed to slowly warm, and stirred
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overnight at room temperature. The basic solution was then
vashed twice with dichloromethane (150 mL) and then
icidified with 6 M aqueous HC1. The acidic mixture was
hen extracted twice with dichloromethane (150 mL). The
>rganic layers were pooled, washed withdistilled water (100
nL), dried over anhydrous magnesium sulfate, and
oncentrated under reduced pressure.
Carbobenzoxy-L-alanine (6a).-TLC (ethyl acetate/
=
lexanes, 1/1, v/v) Rf
0.45. *H NMR (CDC1S/TMS,
>0MHz) 5 2.4 (3H, d), 4.4 (1H, t), 4.7 (1H, m), 5.3 (2H, s),
7.3(5H,s), 11.2 (1H, m).
Carbobenzoxy-L-valine (6b).-TLC (ethyl acetate/
hexanes, 1/1, v/v) Rf = 0.80. iH NMR (CDC13 /TMS,
60MHz) 8 1.5 (6H, d), 2.3 (IH,m), 4.3 (IH,t), 4.7 (IH,m),
5.2 (2H, s), 7.2 (5H,s), 11.3 (IH,m).
(6c). -TLC (ethyl acetate/
exanes, 1/2, v/v) Rf = 0.35. *H NMR (CDCI3/TMS,
0MHz) 8 1.3 (6H, d), 2.2 (3H, m), 4.5 (IH,t), 4.9 (IH,m),
.3 (2H, s), 7.3 (5H,s), 11.4 (IH,m).
General Procedure for Preparation of Carbobenzoxydipeptide methyl esters (7a-c).-A cold (10°C) solution of
0.015 mole of the appropriate carbobenzoxy-amino acid
(6a-c) in 20 mL anhydrous dimethyl formamide (DMF) was
treated with 2.0 mL (0.015 mole) anhydrous triethylamine.
After 10 minutes the cold solution was treated with 1.2 mL
(0.014 mole) ethyl chloroformate. The mixture was stirred
for 1 hour at -10°C and then combined with a precooled
(0°C) solution containing 2.60 g (0.015 mole) Lphenylalanine methyl ester hydrochloride and 2.0 mL
(0.015 mole) triethyl amine in 20 mL anhydrous DMF. The
mixture was stirred at 0°C for 3 hours, allowed to warm to
oom temperature, and stirred overnight. The mixture was
len partitioned between the layers of ethyl acetate (200
mL) and aqueous 1 MNaOH (150 mL). The organic layer
as washed with distilled water (150 mL), aqueous 1 MHC1
50 mL), and distilled water (150 mL) again. The organic
ayer was dried over anhydrous magnesium sulfate and
vaporated under reduced pressure.
methyl ester
=
(CDC1
*H
NMR
'a).~TLC (chloroform) Rf 0.18
3/TMS,
d),
(3H,
s),
(2H,
m),
4.5
(3H,
d),
(2H,
2.7
3.8
MHz) 8 2.3
m),
(2H,
s),
(5H,
s),
(5H,s).
6.9
7.3
(IH,
m),
(IH,
7
5.4
5.0

ICarbobenzoxy-L-leucine

ICarbobenzoxy-L-alanyl-L-phenylalanine

methyl ester
= 0.27. lHNMR (CDC1 /TMS,
(chloroform)
3
&J.--TLC
Rf

ICarbobenzoxy-L-valyl-L-phenylalanine
tCarbobenzoxy-L-leucyl-L-phenylalanine

•MHz) 8 1.5 (6H, d), 2.3 (IH, m), 2.6 (2H, d), 3.7 (3H, s),
5 (2H, m), 4.7 (IH,m), 5.0 (IH,m), 5.3 (2H, s), 7.0 (5H, s),
!(5H,s).
methyl ester
= 0.38. *HNMR (CDC1 /TMS,
(chloroform)
Rf
3
CJ.--TLC
MHz) 8 1.2 (6H, d), 2.2 (3H, m), 2.7 (2H, d), 3.6 (3H, s),
3 (2H, m), 4.7 (IH,m), 5.0 (IH,m), 5.5 (2H, s), 7.0 (5H, s),

General Procedure

for

Preparation
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of Carbobenzoxy-

dipeptide acids (8a-c).--A solution of the appropriate
carbobenzoxy-dipeptide methyl ester (0.010 to 0.015 mole)

in 100 mL methanol was mixed with 50 mL aqueous 1 M
NaOH. The mixture was stirred overnight at room
temperature. The resulting mixture was diluted with200 mL
distilled water and acidified to pH 3.0 with aqueous 6 M
HC1. The mixture was then concentrated to about one half
volume under reduced pressure. The cloudy mixture was
extracted twice with ethyl acetate (150 mL). The organic
layers were combined, washed withdistilled water (150 mL),
dried over anhydrous magnesium sulfate, and then
evaporated under reduced pressure.
(8a). --TLC
Carbobenzoxy-L-alanyl-L-phenylalanine
(chloroform) Rf = 0.18 lH NMR (CDCI3/TMS, 6OMH2) 8
2.3 (3H, d), 2.7 (2H, d), 4.6 (2H, m), 4.9 (IH, m), 5.0 (IH,
m), 5.4 (2H, s), 6.9 (5H, s), 7.5 (5H,s), 10.8 (IH, m).
(8b). --TLC
Carbobenzoxy-L-valyl-L-phenylalanine
(chloroform) Rf = 0.27. *H NMR (CDCl/TMS, 60MHz)
1.5 (6H, d), 8 2.3 (IH, m), 2.6 (2H, d), 4.5 (2H, m), 4.8 (IH,
m), 5.0 (IH,m), 5.3 (2H, s), 7.0 (5H, s), 7.4 (5H,s), 11.0 (IH,
m).
(8c). --TLC
Carbobenzoxy-L-leucyl-L-phenylalanine
(chloroform) Rf = 0.38. lHNMR (CDCl^/TMS, 60MHz) 8
1.2 (6H, d), 2.2 (3H, m), 2.7 (2H, d), 4.5 (2H, m), 4.7 (IH,
m), 5.0 (IH,m), 5.5 (2H, s), 7.0 (5H, s), 7.4 (5H,s), 11.2 (IH,
m).
General Procedure for Coupling Cbz-dipeptide to 3(S)amino-4-phenyl- 1-N-piperdine (or pyrrolidine) -2 (S) -butanol
(9a-f).—A precooled solution (15°C) of the appropriate
carbobenzoxy-dipeptide (8a-c) (0.35 mmol) in 10 mL
anhydrous DMF was treated with 56 uL (0.40 mmol)
triethyl amine. The mixture was allowed to react at -15°C
for 30 minutes and was then treated with 34 uL (0.35 mmol)
ethyl chloroformate. The mixture was stirred under N2
atmosphere for 1 hour at -15°C. A precooled (0°C) solution
containing 0.32 mmole of either 5a or 5b in 25 mL
anhydrous DMFand 125 uL (1.0 mmole) triethylamine was
then added to the mixed anhydride of the Cbz-dipeptide.
The combined mixture was stirred under N2 at 0°C for 4
hours, allowed to warm to room temperature, and stirred
overnight at room temperature. The mixture was
partitioned between the layers of ethyl acetate (250 mL) and
0.01 Maqueous NaOH. The organic layer was removed and
saved. The aqueous layer was extracted again with another
250 mL ethyl acetate. The organic layers were pooled,
washed withdistilled water (100 mL), dried over anhydrous
magnesium sulfate, and evaporated under reduced pressure.

3(S)-[Cbz-L-alanyl-L-phenylalanylamino]-4-phenyl-1-

N-piperdine-2(S) -butanol (9a).-0A57 g. TLC (10%
ethanol/ethyl acetate) Rf = 0.17, ]H NMR (DMSO-d 6 60
MHz) 8 1.7 (2H, d), 1.9 (4H, m), 2.0 (4H, t), 2.4 (5H, m), 2.7
(2H, d), 3.1 (2H, d ), 3.7 (IH,m), 4.6 (3H, m), 5.0 (IH, m),
5.4 (2H, s), 6.9 (5H, s), 7.1 (5H,s), 7.3 (5H, s).
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3(S)-[Cbz-L-valyl-L-phenylalanylamino]-4-phenyl-1-N(9b).-0A35 g. TLC (10%
piperdine-2(S)-butanol

ethanol/ethyl acetate) Rf = 0.23, lH NMR (DMSO-d 6 60
MHz) 8 1.3 (6H, d), 1.5 (2H, t), 1.8 (4H, m), 1.9 (4H, t), 2.5
(3, m), 2.7 (2H, d), 3.1 (2H, d ), 3.7 (1H, m), 4.6 (3H, m), 5.0
(1H, m), 5.4 (2H, s), 6.8 (5H, s), 7.1 (5H,s), 7.4 (5H, s).

3(S)-[Cbz-L-leucyl-L-phenylalanylamino]-4-phenyl-1-N(.9cj.--0.128
g. TLC (10%
piperdine-2(S)-butanol
ethanol/ethyl acetate) Rf = 0.26, J H NMR (DMSO-d 6 60

MHz) 8 1.3 (6H, d), 1.5 (2H, t), 1.8 (4H, m), 1.9 (4H, t), 2.5
(7, m), 2.7 (2H, d), 3.1 (2H, d ), 3.7 (1H, m), 4.6 (3H, m), 5.0
(1H, m), 5.4 (2H, s), 6.9 (5H, s), 7.3 (5H,s), 7.5 (5H, s).
3(S) -[Cbz-L-alanyl-L-phenylalanylamino]-4-phenyl- 1N-pyrrolidine-2(S)-butanol (9d).-0A67 g. TLC (15%
ethanol/ethyl acetate) Rf = 0.23, J H NMR (DMSO-d 6 60
MHz) 8 1.8 (4H, t), 2.0 (4H, m), 2.4 (5H, m), 2.9 (2H, d), 3.3
(2H, d ), 3.8 (1H, m), 4.6 (3H, m), 5.0 (1H, m), 5.3 (2H, s),
6.8 (5H, s), 7.1 (5H,s), 7.5 (5H, s).
3(S) -[Cbz-L-valyl-L-phenylalanylaminoJ-4-phenyl- 1-Npyrrolidine-2(S)-butanol (9e).~0.U7 g. TLC (15%
ethanol/ethyl acetate) Rf = 0.35, lH NMR (DMSO-d 6 60
MHz) 8 1.3 (6H, d), 1.7 (4H, m), 209 (4H, t), 2.4 (3, m), 2.8
(2H, d), 3.2 (2H, d ), 3.8 (1H, m), 4.7 (3H, m), 5.0 (1H, m),
5.3 (2H, s), 6.8 (5H, s), 7.2 (5H,s), 7.5 (5H, s).
3(S) -fCbz-L-leucyl-L-phenylalanylaminoJ-4-phenyl- 1-Npyrrolidine-2(S)-butanol (9f).-0.U2 g. TLC (15%
ethanol/ethyl acetate) Rf = 0.41, *H NMR (DMSO-d 6 60
MHz) 8 1.3 (6H, d), 1.8 (6H, m), 2.0 (4H, t), 2.4 (3, m), 2.9
(2H, d), 3.3 (2H, d), 3.8 (1H, m), 4.7 (3H, m), 5.0 (1H, m),
5.3 (2H, s), 6.8 (5H, s), 7.2 (5H,s), 7.5 (5H, s).
General Procedure for Preparation of 3(S)-[Acetyldipeptide-amino]-4-phenyl-1-N- piperdine (or pyrrolidine)2(S)-butanol hydrochloride (70a-f).--A solution of the
carbobenzy protected compound (9a-f) (0.20 mmol) in 250
mL methanol and 1 mL 0.01 M aqueous HC1 was treated
with 0.050 g pre-moistened 10% Pd-C to form a slurry in a
3 neck flask. H2 gas was bubbled (1 atm) through the rapidly
stirring mixture at room temperature for three hours. The
mixture was then filtered to remove the catalyst, and the
solvent was evaporated under reduced pressure. The crude
amine hydrochloride was dissolved in 10 mL dimethyl
sulfoxide (DMSO) and treated with 125 uL (0.10 mole)
triethyl amine. The mixture was stirred at room temperature
for 30 minutes. Acetic anhydride (95 uL, 1.0 mmol) was
added, and the mixture was stirred overnight at room
temperature. Cold diethyl ether (200 mL) was added to
precipitate the product. The liquid was decanted, and the
white solid was washed three times with cold ether (100
mL). The crude product was purified by Sephadex LH-20
column chromatography (column size 5 cm dia. x 80 cm)
using methanol as the mobile phase.

3(S)-[Acetyl-L-alanyl-L-phenylalanylamino]-4-phenyl1-N-piperdine-2(S)-butanol (10a).-0.52 g. TLC (1-

butanol/H 2O/acetic acid, 15/2/1) Rf = 0.67, lH NMR
(methanol-d 4 200 MHz) 8 1.689 (2H, d), 1.987 (4H, m),
2.010 (4H, t), 2.305 (3H, d), 2.210 (2H, s) 2.462 (4H, m),
2.597 (2H, d), 3.715 (1H, m), 4.610 (3H, m), 4.984 (3H, m),
6.949 (5H, s), 7.212 (5H,s).
3(S) -fAcetyl-L-valyl-L-phenylalanylaminoJ-4-phenyl- 1(10b).-0.63
N-piperdine-2(S)-butanol
g. TLC (1butanol/H 2O/acetic acid, 15/2/1) Rf = 0.72, lH NMR
(methanol-d 4 200 MHz) 8 1.452 (6H, d), 1.689 (2H, d), 1.989
(4H, m), 2.016 (4H, t), 2.291 (1H, m), 2.219 (2H, s) 2.458
(4H, m), 2.599 (2H, d), 3.720 (1H, m), 4.613 (3H, m), 4.989
(3H, m), 6.959 (5H, s), 7.203 (5H,s).

3(S)-[Acetyl-L-leucyl-L-phenylalanylamino]-4-phenyl-1(10c).-0Al g. TLC (1N-piperdine-2(S)-butanol
butanol/H 2O/acetic acid, 15/2/1) Rf = 0.79, !H NMR
(methanol-d 4 200 MHz) 8 1.298 (6H, d), 1.689 (2H, d), 1.990
(4H, m), 2.017 (4H, t), 2.199 (3H, m), 2.220 (2H, s) 2.455
(4H, m), 2.601 (2H, d), 3.721 (1H, m), 4.614 (3H, m), 4.990
(3H, m), 6.960 (5H, s), 7.213 (5H,s).

3(S)-[Acetyl-L-alanyl-L-phenylalanylamino]-4-phenyl1-N-pyrrolidine-2(S)-butanol (10d).-0.7l g. TLC (1
butanol/H 2O/acetic acid, 15/2/1) Rf = 0.55, l
H NMR

(methanol-d 4 200 MHz) 8 1.999 (4H, t), 2.135 (4H, t), 2.315
(3H, d), 2.211 (2H, s) 2.457 (4H, m), 2.631 (2H, d), 3.715
(1H, m), 4.615 (3H, m), 4.991 (3H, m), 6.999 (5H, s), 7.242
(5H,s).
3(S) [Acetyl-L-valyl-L-phenylalanylaminoJ-4-phenyl- 1N-pyrrolidine-2(S)-butanol (10e).-0.75 g. TLC (1butanol/H 2O/acetic acid, 15/2/1) Rf = 0.68, l
H NMR
(methanol-d 4 200 MHz) 8 1.452 (6H, d), 2.009 (4H, t), 2.160
(4H, t), 2.396 (1H, m), 2.220 (2H, s) 2.488 (4H, m), 2.601
(2H, d), 3.722 (1H, m), 4.655 (3H, m), 4.993 (3H, m), 6.979
(5H, s), 7.301 (5H,s).

3(S)-[Acetyl-L-leucyl-L-phenylalanylamino]-4-phenyl-1N-pyrrolidine-2(S)-butanol (70/J.-O.81 g. TLC (1butanol/H 2O/acetic acid, 15/2/1) Rf = 0.81, *H NMR
(methanol-d 4 200 MHz) 8 1.299 (6H, d), 1.990 (4H, t), 2.020
(4H, t), 2.197 (3H, m), 2.221 (2H, s) 2.462 (4H, m), 2.611
(2H, d), 3.725 (1H, m), 4.615 (3H, m), 4.997 (3H, m), 6.976
(5H, s), 7.200 (5H,s).

Results and Discussion
Our synthetic plan of the potential cathepsin D
inhibitors involved three phases: (a) preparation of the
protected hydroxyethyl amine isostere portion (b)
preparation of the carbobenzoxy protected dipeptide portion
and (c) condensation and deblocking of the peptide and nonpeptide portions. The hydroxyethyl amine isosteres were
prepared from a tert- butoxycarbonyl- (BOC) chiral amino
aminoalkyl epoxide (Scheme 1). The novel chiral aminoalkyl
epoxides were first reported by Evans et al. (1985) and have
been subsequently used successfully in the preparation of
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Scheme 1
several HIV-1 aspartyl protease inhibitors with hydroxyethyl

amine isosteres (Fassler et al., 1996; Barrish et al., 1994). The
alkene was prepared from a protected chiral aminoaldehyde
by reaction with a ylide (triphenyl phosphonium methylide).

The olefin was converted to the chiral epoxide with metachloroperoxybenzoic acid (MCPBA) in methylene chloride.
This reaction takes place with retention of stereochemical
configuration at the a-carbon of the protected
aminoaldehyde. The ylide attack on the diastereotopic faces
of the aldehyde is nonspecific, and the epoxide obtained is a
separable mixture of isomers easily distinguished by NMR
adsorption on the C2 proton (8 3.7 and 4.1) (Evans et al.,
1985). Separation of the diastereomers was accomplished by
using ethyl
silica gel column chromatography
acetate/hexanes (25% v/v) as the mobile phase. Normally the
2S,3S epoxide is utilized to prepare HIV-1 protease
inhibitors with the desired R-hydroxyethyl amine isostere
(Fassler et al., 1996; Barrish et al., 1994). However, since the
S-hydroxyethyl amine isostere is reported to be the more
active isomer for cathepsin D inhibition (Kick, 1997), we
utilized the 2R,3S protected amino epoxide in our synthesis
(Scheme 1). Piperdine or pyrrolidine was used as a
nucleophile in the preparation of the cyclized tertiary
amines. The BOC protecting group was removed from the
primary amine with non-aqueous acid (2 M HCl in
chloroform).

Journal
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Preparation of the protected peptide portion of the
target molecules was accomplished in the following manner.
A basic solution of the chosen amino acid was condensed

with benzyl chloroformate to provide, after acidification and
purification, the carbobenzoxy (Cbz) protected amino acid.
The Cbz-amino acid was then coupled to a separate amino
acid methyl ester by a mixed anhydride coupling technique
utilizing ethyl chloroformate. The C-terminus of the Cbz
protected dipeptide methyl ester was then deblocked in
aqueous sodium hydroxide, followed by acidification
(Scheme 2). In the third phase of our synthesis, the Cbzwas
protected
dipeptide
condensed
with ethyl
chloroformate and then reacted with the basified primary
amine of the hydroxyethyl amine isostere portion (Scheme
3). The Cbz protecting group of the resulting compound was
then removed and replaced with an acetyl group. The final
product was purified by sephadex HP chromatography and
characterized by TLC and 'H NMR.
Conclusions
Our synthetic route shows a great deal of promise for
the future synthesis of similar hydroxyethyl amine isosteres.
The synthetic inhibitors willbe screened for their inhibition
of cathepsin D first by spectrophotometric assay techniques,
and then detailed kinetic data willbe determined by more
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sensitive fluorometric techniques (Kick et al., 1997). The
inhibition constants for these synthetic compounds willbe
reported in the near future.
—The authors wish to thank the
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